Compare STTK & PRTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | PRTH |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 440.2M |
| IPO Year | 2020 | 2016 |
| Metric | STTK | PRTH |
|---|---|---|
| Price | $4.55 | $7.90 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | ★ $15.40 | $8.03 |
| AVG Volume (30 Days) | ★ 841.6K | 427.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 319.35 |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $8.54 |
| Revenue Next Year | $14.28 | $7.48 |
| P/E Ratio | ★ N/A | $20.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $4.57 |
| 52 Week High | $8.33 | $7.94 |
| Indicator | STTK | PRTH |
|---|---|---|
| Relative Strength Index (RSI) | 36.65 | 69.53 |
| Support Level | $4.38 | $7.76 |
| Resistance Level | $7.66 | $7.94 |
| Average True Range (ATR) | 0.39 | 0.03 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 13.92 | 55.00 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
Priority Technology Holdings Inc is a fintech company that provides payment and banking-related solutions, including services for collecting, storing, lending, and transferring money for businesses. The company has three reportable segments: i) Merchant Solutions: Provides full-service acquiring and payment-enabled solutions for B2C transactions, ii) Payables: Provides AP automation solutions to corporations, software partners and FIs in addition to improving cash flows by providing instant access to working capital and iii) Treasury Solutions: Provides embedded finance and BaaS solutions to customers to modernize legacy platforms and accelerate software partners' strategies to monetize payments. The majority of the company's revenue is derived from the Merchant Solutions segment.